An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi(University of Salento), Catherine J. Harmer(Oxford Health NHS Foundation Trust), Philip J. Cowen(Oxford Health NHS Foundation Trust), Toby Pillinger(King's College London), Rachel Upthegrove(Warneford Hospital), Amanda Adler, Maxime Taquet(Mansfield University), Robert A. McCutcheon(MRC London Institute of Medical Sciences), Marco Solmi(University of Padua), Ivan Koychev(John Radcliffe Hospital), Oliwia Dziwisz(Warneford Hospital), Ana Ghenciulescu(Warneford Hospital)
Cited by 58
Related Papers
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
|Molecular Psychiatry|2021|3.6k
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
|The Lancet Psychiatry|2021|2.2k
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls
|World Psychiatry|2017|1.7k
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
|The Lancet Psychiatry|2019|1.5k